Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
24 studies found for:    "potassium-aggravated myotonia" OR "Myotonic Disorders" OR "Myotonia Fluctuans"
Show Display Options
RSS Create an RSS feed from your search for:
"potassium-aggravated myotonia" OR "Myotonic Disorders" OR "Myotonia Fluctuans"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Lamotrigine as Treatment of Myotonia
Conditions: Dystrophia Myotonica Type 1;   Myotonia Congenita;   Paramyotonia Congenita;   Hyperkalemic Periodic Paralysis;   Potassium-Aggravated Myotonia
Interventions: Drug: Lamotrigine;   Drug: Placebo
2 Completed Characteristics of Nondystrophic Myotonias
Conditions: Nondystrophic Myotonias;   Myotonia Congenita;   Myotonic Disorders
Intervention:
3 Unknown  RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Conditions: Myotonic Dystrophy;   Sudden Cardiac Death
Interventions: Procedure: Electrophysiological study;   Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant
4 Completed Methylphenidate in Myotonic Dystrophy Type 1
Condition: Dystrophia Myotonica 1
Interventions: Drug: Methylphenidate;   Drug: Placebo
5 Completed DM1 Heart Registry - DM1 Respiratory Registry
Condition: Myotonic Dystrophy
Intervention:
6 Recruiting Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy
Condition: Myopathy
Intervention: Device: Nocturnal ventilation
7 Recruiting Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Conditions: Myotonic Dystrophy;   Muscular Dystrophy, Facioscapulohumeral;   Muscular Dystrophy
Intervention:
8 Recruiting Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
Conditions: Muscle Myopathies;   Muscular Dystrophy;   Inherited Neuromuscular Conditions
Intervention:
9 Recruiting A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: ISIS-DMPKRx;   Drug: Placebo
10 Recruiting Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy
Interventions: Drug: Mexiletine;   Drug: Placebo
11 Recruiting Multicenter Observational Study of Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention:
12 Recruiting Study of Ranolazine in Myotonia Congenita
Condition: Myotonia Congenita
Intervention: Drug: Ranolazine
13 Recruiting Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy
Condition: Myotonic Dystrophy Type 1
Intervention:
14 Unknown  Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation
15 Completed Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy
Condition: Myotonic Muscular Dystrophy
Intervention:
16 Recruiting Relations Between Myotonia and Fitness
Condition: Congenital Myotonia
Intervention: Other: Training
17 Unknown  Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: rhIGF-I/rhIGFBP-3;   Drug: placebo
18 Completed Mexiletine and Non Dystrophic Myotonias
Conditions: Non-dystrophic Myotonias;   Paramyotonia Congenita;   Myotonia Congenita
Interventions: Drug: Mexiletine;   Drug: placebo
19 Recruiting Observational Prolonged Trial in Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention: Behavioral: Behavioural change intervention
20 Completed Efficacy and Safety of DHEA for Myotonic Dystrophy
Condition: Myotonic Dystrophy
Intervention: Drug: dehydroepiandrosterone 100 and 400 mg

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years